BioMarin Stops Voxzogo Development for Noonan Syndrome

BioMarin discontinued Voxzogo development in Noonan syndrome due to study feasibility and the treatment landscape, while stating the decision was unrelated to safety or efficacy. Voxzogo generated $472 million in first-half 2026 sales, up 9% year over year, and BioMarin reaffirmed expected 2026 sales of $1.00-$1.05 billion. Growth and potential 2027 hypochondroplasia expansion are offset by intensified competition from Ascendis' once-weekly Yuviwel and a potential oral entrant from BridgeBio; BioMarin will receive 20% U.S. and 18% ex-U.S. royalties on Yuviwel sales through May 2030 under their patent settlement.

Analysis

The relevant valuation issue is not the discontinued indication's standalone revenue, but the signal that Voxzogo's expansion optionality is narrowing while its core franchise enters a three-product market. BMRN's royalty structure creates a partial hedge against ASND share gains, yet it is economically inferior to retaining branded sales: every $100 of U.S. Yuviwel sales that displaces Voxzogo recovers only $20 of revenue before considering the materially higher gross-profit contribution of BMRN's own product. This should lower the terminal-growth and peak-sales assumptions embedded in BMRN's franchise multiple over the next 6-18 months.

ASND has the clearest near-term commercial setup because weekly administration can drive switching in a chronic pediatric setting, especially if payer access is comparable. The settlement also removes an injunction/ITC-tail-risk discount and makes Yuviwel uptake incrementally accretive to BMRN rather than purely destructive; that alignment could reduce aggressive contracting, supporting category expansion. The key 1-3 month data point is initial prescription persistence and formulary status, not headline new-start volume, since switching rates determine whether the market expands or merely reallocates.

BBIO is the higher-beta contrarian beneficiary if an oral entrant changes treatment sequencing, but its prospective approval is also the largest risk to both injectable franchises. The market may be understating the possibility that oral therapy expands treatment among families unwilling to accept chronic injections, preserving total category growth; however, efficacy, safety, pediatric labeling and reimbursement will determine whether this is additive. Repeated program exits leave BMRN's hypochondroplasia decision as a binary 2027 offset, and any safety-related label language or slower-than-guided core demand would invalidate a defensive view on the stock.

Key Decisions for Investors

• Maintain a 3-6 month long ASND / short BMRN pair, sized modestly: weekly convenience plus removal of litigation overhang should support ASND relative estimates, while BMRN faces a lower expansion-optionality multiple. Reassess if Yuviwel payer coverage lags Voxzogo materially or if BMRN reports stable-to-rising share and raises Voxzogo guidance.
• Do not add outright BMRN on the development discontinuation alone. Set an alert around the next earnings call for net-price trends, persistence, switching commentary and explicit 2027 hypochondroplasia revenue assumptions; a guidance raise driven by durable core demand would be the falsifier for the relative short leg.
• Accumulate BBIO only ahead of a clearly defined FDA decision-date/risk-management plan, rather than on the filing headline. A small call-spread position expiring after the expected mid-2027 launch window offers asymmetric exposure to oral-therapy approval; exit if regulatory review identifies efficacy or pediatric-safety deficiencies.
• Monitor BMRN royalty disclosures versus ASND reported sales quarterly: royalties below the implied 18-20% rate, after geographic mix, would signal delayed commercialization or lower-than-expected compliance and weaken the thesis that the settlement cushions competitive losses.